I don’t think they will pursue more shining things short of partnership etc., that seems to be what is being telegraphed. Completing the remaining component of the BLA is likely the shortest path to approval, no more trials needed there. Maybe that is imminent news and we just don’t know it. Money/time has been expended pursuing Cancer and NASH; you can choose to view that as lost time/$ or you can view it as expanding the potential worth/attractiveness of the company vis a vis buyout or partnership. I am inclined toward the later and grateful we have multiple shots on goal to hedge and increase the odds of success.